Newscope Capital Provides Dial-In Information for Special Meeting

April 1, 2021
News

TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF) would like to provide the following dial-in information for the Company’s upcoming Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 5, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.

The main purpose of the Meeting is to obtain the approval of the shareholders to change the name of the Company to PharmaTher Ltd. and an amendment to the Articles of the Company in connection with the name change.

In consideration of the COVID-19 pandemic, the Company asks that shareholders and proxyholders attend the Meeting via teleconference and not attend the Meeting in person at the address provided on the Notice of Special Meeting of Shareholders. In the event that the Ontario Provincial Government imposes a province-wide lockdown, no shareholder or proxyholder will be permitted to attend the Meeting in person.

About Newscope Capital Corporation

Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF) is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat neuropsychiatric, neurodegenerative and pain disorders.

Learn more at: PharmaTher.com and follow us on Twitter and LinkedIn.

For more information, please contact:        

Fabio Chianelli
Chief Executive Officer
Newscope Capital Corporation
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.